2. 2. 24. ABSORPTION SPECTROPHOTOMETRY, INFRARED If an FT-IR instrument is used, the absorption is compensated by recording the spectra for the solvent and the sample successively The solvent absorbance, corrected by a compensation factor, is subtracted using calculation software
The Ph. Eur. revises its general chapter on Infrared Absorption . . . The Ph Eur revises its general chapter on Infrared Absorption Spectrophotometry At its 160th session (March 2018) the Ph Eur Commission adopted a new version of one of its major general methods, which has undergone extensive revision
European Pharmacopoeia 5. 0 - SHIMADZU CORPORATION In 2005, the European Pharmacopoeia 5 0 was introduced, and these standards were revised In this article, we introduce the points of revision and how the Shimadzu FTIR series addresses these changes
Infrared Spectrophotometry 2. 2. 24 Guidelines | PDF | Infrared . . . - Scribd What are the advantages of using Fourier-transform infrared (FT-IR) spectrometers, and what common components are involved in their operation? Fourier-transform infrared (FT-IR) spectrometers offer advantages such as broadband spectral data collection and high-resolution capabilities
NIRS Guideline Final - European Medicines Agency Summary details of the NIRS apparatus should be provided, including the make and model number of the instrument, the light dispersion principle of the optical system (e g grating, FT-IR), the detector type (e g silicon, lead sulphide), the measurement method or mode (e g reflectance, transmission, transflectance) and the wavelength
General Chapters: lt;197 gt; SPECTROPHOTOMETRIC IDENTIFICATION TESTS Spectrophotometric tests contribute meaningfully toward the identification of many compendial chemical substances The test procedures that follow are applicable to substances that absorb IR and or UV radiation (see Spectrophotometry and Light-Scattering 851)
European Pharmacopoeia 2. 2. 24 Reference Standard ICL's PhEur 2 2 24 Reference Standard is a calibration standard certified to conform to the requirements of Chapter 2 2 24 of the European Pharmacopoeia